PureTech Health PLC PRTC

Morningstar Rating
GBX117.25 −0.95 (0.80%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRTC is trading at a LOCK|^Kk!$< premium.
Price
£1.18
Fair Value
LOCK|^fVsF$>
Uncertainty
LOCK|ql
1-Star Price
LOCK|ssfRs^r
5-Star Price
LOCK|#>dZNJ
Economic Moat
LOCK|$gs
Capital Allocation
—

News

Trading Information

Previous Close Price
GBX118.20
Day Range
GBX117.00–118.20
52-Week Range
GBX106.60–143.60
Bid/Ask
GBX117.00 / GBX118.20
Shares Outstanding
245.18M
Market Cap
GBX28.75B
Volume/Avg
90,161 / 653,793

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
62.19
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
62

Valuation

Metric
PRTC
Price/Earnings (Normalized)
—
Price/Book Value
1.01
Price/Sales
62.19
Price/Cash Flow
—
Price/Earnings
PRTC

Financial Strength

Metric
PRTC
Quick Ratio
4.40
Current Ratio
4.60
Interest Coverage
0.94
Quick Ratio
PRTC

Profitability

Metric
PRTC
Return on Assets (Normalized)
−44.94%
Return on Equity (Normalized)
−72.18%
Return on Invested Capital (Normalized)
−57.62%
Return on Assets
PRTC

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|j%wv>@LOCK|%^N>v$136B
Regeneron Pharmaceuticals Inc
REGN
LOCK|y!lj$rLOCK|$hs!N$99B
Moderna Inc
MRNA
LOCK|mN#!f&!LOCK|bq$87B
argenx SE ADR
ARGX
LOCK|ymMzp&LOCK|C$R$61B
BeOne Medicines Ltd ADR
ONC
LOCK|bx$XcX?LOCK|M@#$48B
Royalty Pharma PLC Class A
RPRX
LOCK|hq^hl!WLOCK|$#nj$31B
Incyte Corp
INCY
LOCK|DR$#<!LOCK|T!$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|Z>!jqT#LOCK|^?KX$21B
BioNTech SE ADR
BNTX
LOCK|!t<LlBpLOCK|&@$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|?WXcHdLOCK|%w@$15B

Sponsor Center